Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4681-4688

  McCallum, Matthew ^a,b   Oliveira, Maureen ^a   Ibanescu, Ruxandra Ilinca ^a   Kramer, Victor G ^a,b   Moisi, Daniela ^a   Asahchop, Eugene L ^a   Brenner, Bluma G ^a   Harrigan, P Richard ^c   Xu, Hongtao ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; ETRAVIRINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; LYSINE; RNA DIRECTED DNA POLYMERASE; VALINE;

ALLELE; ARTICLE; DRUG COMPETITION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPOTHESIS; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SUBSTITUTION REACTION; ULTRADEEP SEQUENCING;

ANTI-HIV AGENTS; CELL LINE; CODON; HIV REVERSE TRANSCRIPTASE; HUMANS; MUTATION; PYRIDAZINES;

EID: 84884262354     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01029-13     Document Type: Article

References (50)

1. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD. 2011. 2011 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 19:156-164.
2. Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, Boven K, Picchio G. 2012. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J. Acquir. Immune Defic. Syndr. 59:39-46.
3. Tambuyzer L, Vingerhoets J, Azijn H, Daems B, Nijs S, de Béthune M-P, Picchio G. 2010. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirinecontaining regimen in the DUET-1 and DUET-2 clinical studies. AIDS Res. Hum. Retrovir. 26:1197-1205.
4. Schader SM, Oliveira M, Ibanescu R-I, Moisi D, Colby-Germinario SP, Wainberg MA. 2012. In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine. Antimicrob. Agents Chemother. 56:751-756.
5. Scherrer AU, Hasse B, von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, Bucher HC, Ledergerber B, Gunthard HF. 2009. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Med. 10:647-656.
6. Tambuyzer L, Nijs S, Daems B, Picchio G, Vingerhoets J. 2011. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J. Acquir. Immune Defic. Syndr. 58:18-22.
7. Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, Toni TD, Tremblay CL. 2011. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob. Agents Chemother. 55:600-607.
8. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. 2010. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents Chemother. 54:718-727.
9. Asahchop EL, Wainberg MA, Oliveira M, Xu H, Brenner BG, Moisi D, Ibanescu IR, Tremblay C. 2013. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. AIDS 27:879-887.
10. Xu HT, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, Schader SM, Han Y, Quan Y, Sarafianos SG, Wainberg MA. 2013. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine. Antimicrob. Agents Chemother. 57:3100-3109.
11. Mansky LM, Temin HM. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
12. Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH. 2010. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J. Virol. 84:9864-9878.
13. Martinez MA, Vartanian JP, Wain-Hobson S. 1994. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc. Natl. Acad. Sci. U. S. A. 91:11787-11791.
14. Mulder LC, Harari A, Simon V. 2008. Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. U. S. A. 105:5501-5506.
15. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD. 2005. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1:e6. doi:10.1371 /journal.ppat.0010006.
16. Fourati S, Malet I, Lambert S, Soulie C, Wirden M, Flandre P, Fofana DB, Sayon S, Simon A, Katlama C, Calvez V, Marcelin AG. 2012. E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. AIDS 26:1619-1624.
17. Turner D, Brenner B, Mosis D, Liang C, Wainberg MA. 2005. Substi-tutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs. MedGenMed 7:69.
18. Deforche K, Camacho R, Laethem KV, Shapiro B, Moreau Y, Rambaut A, Vandamme AM, Lemey P. 2007. Estimating the relative contribution of dNTP pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo. J. Comput. Biol. 14:1105-1114.
19. Buckton AJ, Harris RJ, Pillay D, Cane PA. 2011. HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: a systematic review and meta-analysis. Antivir. Ther. 16:9-16.
20. Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM, Frenkel LM, Hazelwood JD, Johnson VA, Kearney M, Kovacs A, Kuritzkes DR, Metzner KJ, Nissley DV, Nowicki M, Palmer S, Ziermann R, Zhao RY, Jennings CL, Bremer J, Brambilla D, Mellors JW. 2006. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J. Clin. Microbiol. 44:2612-2614.
21. Paredes R, Clotet B. 2008. HIV drug resistance testing. Eur. Infect. Dis. 2:52-62.
22. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF. 1989. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17:2503-2516.
23. Cha RS, Zarbl H, Keohavong P, Thilly WG. 1992. Mismatch amplification mutation assay (MAMA): application to the c-H-ras gene. Genome Res. 2:14-20.
24. Johnson JA, Li JF, Wei X, Lipscomb J, Bennett D, Brant A, Cong ME, Spira T, Shafer RW, Heneine W. 2007. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS One 2:e638. doi:10.1371/journal.pone .0000638.
25. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
26. Oliveira M, Moisi D, Spira B, Cox S, Brenner BG, Wainberg MA. 2009. Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations. Antimicrob. Agents Chemother. 53:1683-1685.
27. Kuiken C, Foley B, Leitner T, Apetrei C, Hahn B, Mizrachi I, Mullins J, Rambaut A, Wolinsky S, Korber B. 2010. HIV sequence compendium 2010. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
28. Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. 2007. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J. Virol. Methods 146:136-146.
29. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. 2011. Accurate sampling and deep sequencing of the HIV-1 protease gene using PrimerID. Proc. Natl. Acad. Sci. U. S. A. 108:20166-20171.
30. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Soding J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7:539.
31. Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, Paern J, Lopez R. 2010. A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic Acids Res. 38:W695-W699.
32. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum-parsimony methods. Mol. Biol. Evol. 28:2731-2739.
33. Ma J, Dykes C, Wu T, Huang Y, Demeter L, Wu H. 2010. vFitness: a web-based computing tool for improving estimation of in vitro HIV-1 fitness experiments. BMC Bioinformatics 11:261. doi:10.1186/1471-2105-11-261.
34. Auwerx J, Van Nieuwenhove J, Rodríguez-Barrios F, de Castro S, Velázquez S, Ceccherini-Silberstein F, De Clercq E, Ma Camarasa J, Perno C-F, Gago F, Balzarini J. 2005. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs. FEBS Lett. 579:2294-2300.
35. Mulky A, Vu BC, Conway JA, Hughes SH, Kappes JC. 2007. Analysis of amino acids in the beta7-beta8 loop of human immunodeficiency virus type 1 reverse transcriptase for their role in virus replication. J. Mol. Biol. 365:1368-1378.
36. Palmer S, Boltz V, Maldarelli F, McIntyre J, Morris L, Hopley M, Mayers D, Robinson P, Mellors J, Coffin J. 2006. Optimization of allele-specific PCR for drug-resistant HIV variants using patient-specific consensus sequences for primer design. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO.
37. Llibre JM, Santos JR, Puig T, Molto J, Ruiz L, Paredes R, Clotet B. 2008. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J. Antimicrob. Chemother. 62:909-913.
38. Pelemans H, Aertsen A, Van Laethem K, Vandamme AM, De Clercq E, Pérez-Pérez MJ, San-Félix A, Velázquez S, Camarasa MJ, Balzarini J. 2001. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138. Virology 280:97-106.
39. Xu HT, Oliveira M, Quashie PK, McCallum M, Han Y, Quan Y, Brenner BG, Wainberg MA. 2012. Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase. J. Virol. 86:8422-8431.
40. Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA. 2011. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J. Virol. 85:11300-11308.
41. Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, Bishop KN, Kramer B, McMichael AJ, Rambaut A, Iversen AK. 2008. Conserved footprints of APOBEC3G on hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERVK( HML2) sequences. J. Virol. 82:8743-8761.
42. Balzarini J, Camarasa MJ, Perez-Perez MJ, San-Felix A, Velazquez S, Perno CF, De Clercq E, Anderson JN, Karlsson A. 2001. Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV. J. Virol. 75:5772-5777.
43. Bracho MA, Moya A, Barrio E. 1998. Contribution of Taq polymeraseinduced errors to the estimation of RNA virus diversity. J. Gen. Virol. 79(Pt 12):2921-2928.
44. Kozal MJ, Chiarella J, St John EP, Moreno EA, Simen BB, Arnold TE, Lataillade M. 2011. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels. Antivir. Ther. 16:925-929.
45. Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, Leitner T, Lundeberg J, Andersson B, Albert J. 2010. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 5:e11345. doi:10.1371/journal.pone.0011345.
46. Bourinbaiar AS. 1994. The ratio of defective HIV-1 particles to replication-competent infectious virions. Acta Virol. 38:59-61.
47. Kwon YJ, Hung G, Anderson WF, Peng CA, Yu H. 2003. Determination of infectious retrovirus concentration from colony-forming assay with quantitative analysis. J. Virol. 77:5712-5720.
48. Coutsinos D, Invernizzi CF, Xu H, Moisi D, Oliveira M, Brenner BG, Wainberg MA. 2009. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J. Virol. 83:2029-2033.
49. Sunpath H, Wu B, Gordon M, Hampton J, Johnson B, Moosa MY, Ordonez C, Kuritzkes DR, Marconi VC. 2012. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS 26:1679-1684.
50. Theys K, Vercauteren J, Snoeck J, Zazzi M, Camacho RJ, Torti C, Schulter E, Clotet B, Sonnerborg A, De Luca A, Grossman Z, Struck D, Vandamme AM, Abecasis AB. 2013. HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. Antimicrob. Agents Chemother. 57:1053-1056.